Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase I...

Hong Kong, 28 July, 2016- Sihuan Pharmaceutical Holdings Group Ltd. announced that Imigliptin Dihydrochloride received the approval for Phase II/III clinical trials from China Food and Drug Administra...

Sihuan Pharmaceutical Secures CFDA pproval for Imigliptin DihydrochloridePhase II/III Clinical Trials
2017-09-06
SIHUAN PHARMACEUTICAL INVESTS IN PHARMADAX (FOSHAN) CO., LTD.

Hainan Sihuan Pharmaceutical, a wholly-owned subsidiary of the SIHUAN Pharmaceutical, recently entered into agreements (the “Agreements”) with, among others, PharmaDax Inc. (“PharmaDax”). Accordin...

2017-09-01
Sihuan Pharmaceutical Announces 2017 Interim Results

Sihuan Pharmaceutical Announces 2017 Interim Results, Focused in Low-End Markets and Strengthened Product Brand Building, Major Products and Products at Growth Stage Achieved Satisfying Increase, Prof...

2017-08-30
Sihuan Pharmacentical was granted final decision in favour of the Group on the patent infringement claim related to the

The board of directors (the “Board”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company” or “Sihuan Pharmaceutical”, together with its subsidiaries, collectively the “Group”) announces...

2017-08-30
Establishment of United States Research and Development Centre

The board of directors (the “Board”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company” or “Sihuan Pharmaceutical” together with its subsidiaries, the “Group”) announces that the Grou...

2017-08-30
CFDA Granted Approval of Phase I-III Clinical Trials for Birociclib, an Internally Developed Innovative Patented New Dru

The board of directors (the “Board”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company” or “Sihuan Pharmaceutical” together with its subsidiaries, the “Group”) announces that the Chin...

Total 12 Pages  First page  Page up  Page down  Last page

Select

  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012